2025-08-28 21:27:35
Latest Post
Himadri Speciality Chemical Ltd Secures ISCC PLUS Certification
HCLSoftware delivers Digital Independence with AI-Powered Sovereign Collaboration Solutions for Business-Critical Infrastructure
Dr. Agarwal's Health Care Limited and Dr. Agarwal's Eye Hospital Limited announce Merger
SAMHI signs agreement to Lease for ~260-room Mid-Scale Hotel in Hyderabad's Financial District
Rail Vikas Nigam Ltd signs JV agreement with Texmaco Rail & Engineering Ltd
Stock Report
INDOCO Remedies Ltd reports higher consolidated PAT of Rs. 17.04 crore in Q1
Posted On : 2020-08-11 12:44:45( TIMEZONE : IST )
INDOCO REMEDIES LTD. has reported financial results for the period ended June 30, 2020.
Financial Results (Q1 FY 2020-21) - QoQ Comparison
The company has reported total income of Rs.276.12 crores during the period ended June 30, 2020 as compared to Rs.272.49 crores during the period ended March 31, 2020.
The company has posted net profit / (loss) of Rs.17.04 crores for the period ended June 30, 2020 as against net profit / (loss) of Rs.5.36 crores for the period ended March 31, 2020.
The company has reported EPS of Rs.1.85 for the period ended June 30, 2020 as compared to Rs.0.58 for the period ended March 31, 2020.
| Financials | Q1 FY2020-21 | Q4 FY19-20 | % Change |
| Total Income | ₹ 276.12 crs | ₹ 272.49 crs |  1.33% |
| Net Profit | ₹ 17.04 crs | ₹ 5.36 crs | 217.91% |
| EPS | ₹ 1.85 | ₹ 0.58 | 218.97% |
Financial Results (Q1 FY 2020-21) - YoY Comparison
The company has reported total income of Rs.276.12 crores during the period ended June 30, 2020 as compared to Rs.253.31 crores during the period ended June 30, 2019.
The company has posted net profit / (loss) of Rs.17.04 crores for the period ended June 30, 2020 as against net profit / (loss) of Rs.1.85 crores for the period ended June 30, 2019.
The company has reported EPS of Rs.1.85 for the period ended June 30, 2020 as compared to Rs.0.20 for the period ended June 30, 2019.
| Financials | Q1 FY2020-21 | Q1 FY2019-20 | % Change |
| Total Income | ₹ 276.12 crs | ₹ 253.31 crs | 9% |
| Net Profit | ₹ 17.04 crs | ₹ 1.85 crs | 821.08% |
| EPS | ₹ 1.85 | ₹ 0.20 | 825% |
Commenting on the 1st quarter FY21 results, Aditi Panandikar, Managing Director, Indoco Remedies Ltd., said, "In the first quarter, the Company could register a growth of 7.9 % in revenues inspite of Covid-19 crisis. In these challenging times, our teams used digital platforms effectively to establish communication with the customers and maintained uninterrupted supplies of medicines in India and across the world."
Shares of INDOCO REMEDIES LTD. was last trading in BSE at Rs.249.8 as compared to the previous close of Rs. 243.95. The total number of shares traded during the day was 27502 in over 1189 trades.
The stock hit an intraday high of Rs. 257.55 and intraday low of 245. The net turnover during the day was Rs. 6879921.
